Skip to main content
. 2024 Aug 15;39(1):132. doi: 10.1007/s00384-024-04704-w

Table 2.

Tumor characteristics (UICC, Union for International Cancer Control staging system; ns, not specified; TaTME, transanal total mesorectal excision)

Study cohort
TaTME patients
n %
Tumor height (third UICC)  < 6 cm 156 41.3
6–11 cm 208 55.0
 ≥ 12 cm 2 0.5
ns 12 3.2
Clinical UICC stage I 55 14.6
II 48 12.7
III 243 64.3
IV 32 8.5
cT clinical tumor size T1 21 5.6
T2 68 18.0
T3 259 68.5
T4 15 4.0
TX/ns 15 4.0
cN clinical nodal status cN0 108 28.6
cN1 229 60.6
cN2 41 10.8
cM clinical metastases status cM0 346 91.5
cM1 32 8.5
Postoperative UICC stage ypT0/Tis 59 15.6
I 132 34.9
II 58 15.3
III 87 23.0
IV 42 11.1
pT postoperative tumor size T0 64 16.9
T1 41 10.8
T2 122 32.3
T3 140 37.0
T4 11 2.9
N postoperative nodal status pN0 262 69.3
pN1 76 20.1
pN2 40 10.6
M postoperative metastases status cM0 336 88.9
c/pM1 42 11.1
Total 378 100.0